BridgeBio Pharma is seeking a Skeletal Dysplasia Account Manager to drive the launch of Infigratinib, a first-in-class therapy for achondroplasia. This remote role requires 8–10 years in pharma/biotech, focusing on community engagement and providing clinical expertise to support families and healthcare providers.
Join a company that values innovation and ethical standards, offering competitive compensation and comprehensive benefits.
#J-18808-Ljbffr